Large gene delivery to the retina with AAV vectors: are we there yet?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Split AAV-based strategies to restore large gene expression.

References

  1. 1.

    Ciulla TA, Hussain RM, Berrocal AM, Nagiel A. Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. Expert Opin Biol Ther. 2020; 20:565–78.

  2. 2.

    Trapani I, Auricchio A. Has retinal gene therapy come of age? From bench to bedside and back to bench. Hum Mol Genet. 2019;28:R108–R18.

    CAS  Article  Google Scholar 

  3. 3.

    Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–78.

    CAS  Article  Google Scholar 

  4. 4.

    Trapani I, Auricchio A. Seeing the light after 25 years of retinal gene therapy. Trends Mol Med. 2018;24:669–81.

    Article  Google Scholar 

  5. 5.

    Chamberlain K, Riyad JM, Weber T. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods. 2016;27:1–12.

    CAS  Article  Google Scholar 

  6. 6.

    Tornabene P, Trapani I. Can adeno-associated viral vectors deliver effectively large genes? Hum Gene Ther. 2020;31:47–56.

    CAS  Article  Google Scholar 

  7. 7.

    McClements ME, MacLaren RE. Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes. Yale J Biol Med. 2017;90:611–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Patel A, Zhao J, Duan D, Lai Y. Design of AAV vectors for delivery of large or multiple transgenes. Methods Mol Biol. 2019;1950:19–33.

    CAS  Article  Google Scholar 

  9. 9.

    Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001;4:383–91.

    CAS  Article  Google Scholar 

  10. 10.

    Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA. 2000;97:6716–21.

    CAS  Article  Google Scholar 

  11. 11.

    Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2008;16:124–30.

    CAS  Article  Google Scholar 

  12. 12.

    Trapani I. Adeno-associated viral vectors as a tool for large gene delivery to the retina. Genes (Basel). 2019;10:287.

  13. 13.

    Maddalena A, Tornabene P, Tiberi P, Minopoli R, Manfredi A, Mutarelli M, et al. Triple vectors expand AAV transfer capacity in the retina. Mol Ther. 2018;26:524–41.

    CAS  Article  Google Scholar 

  14. 14.

    Pasquini G, Cora V, Swiersy A, Achberger K, Antkowiak L, Muller B, et al. Using transcriptomic analysis to assess double-strand break repair activity: towards precise in vivo genome editing. Int J Mol Sci. 2020;21:1380.

  15. 15.

    Romero-Casanas A, Gordo V, Castro J, Ribo M. Protein splicing: from the foundations to the development of biotechnological applications. Methods Mol Biol. 2020;2133:15–29.

    Article  Google Scholar 

  16. 16.

    Aranko AS, Volkmann G. Protein trans-splicing as a protein ligation tool to study protein structure and function. Biomol Concepts. 2011;2:183–98.

    CAS  Article  Google Scholar 

  17. 17.

    Tornabene P, Trapani I, Minopoli R, Centrulo M, Lupo M, de Simone S, et al. Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci Transl Med. 2019;11:eaav4523.

  18. 18.

    Schmelas C, Grimm D. Split Cas9, not hairs—advancing the therapeutic index of CRISPR technology. Biotechnol J. 2018;13:e1700432.

    Article  Google Scholar 

  19. 19.

    Trapani I, Toriello E, de Simone S, Colella P, Iodice C, Polishchuk EV, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet. 2015;24:6811–25.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Graciana Diez-Roux (TIGEM Scientific Office) for the critical reading of the manuscript.

Funding

AA is funded by Fondazione Telethon, the European Research Council (ERC) (grant number 694323 “EYEGET”) and by the European Union Horizon 2020 and Marie Curie programs (grants number: 825825 “Upgrade” and 813490 “StarT”, respectively). IT receives funding from University of Naples Federico II, STAR Program.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alberto Auricchio.

Ethics declarations

Conflict of interest

IT, PT and AA are co-inventors on patents related to both dual AAV and AAV intein vectors.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trapani, I., Tornabene, P. & Auricchio, A. Large gene delivery to the retina with AAV vectors: are we there yet?. Gene Ther (2020). https://doi.org/10.1038/s41434-020-0174-4

Download citation